[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"her2-positive-or-trop2-positive-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:her2-positive-or-trop2-positive-non-small-cell-lung-cancer":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100637654","study-on-the-mechanism-of-adc-drug-evaluation-based-on-immune-co-culture-of-lung-cancer-organoids-100637654",false,"NCT07610616","Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Availability of patient-derived organoids (PDOs) with matched autologous tumor-infiltrating lymphocytes (TILs) or peripheral blood mononuclear cells (PBMCs) from non-small cell lung cancer (NSCLC) cases.\n* Patients currently undergoing or scheduled to receive Trastuzumab deruxtecan (T-DXd) therapy who meet clinical eligibility criteria.\n* Provision of written informed consent.\n* PDOs exhibiting strong positive HER2 and TROP2 expression by immunohistochemistry (IHC) assigned to the experimental group.\n* PDOs exhibiting weak positive HER2 and TROP2 expression by IHC assigned to the negative control group.\n\nExclusion Criteria:\n\n* PDOs derived from patients with pathologically confirmed small cell lung cancer (SCLC).\n* Unavailability of matched autologous PDOs, TILs, or PBMCs.\n* Presence of any contraindications to T-DXd treatment.\n* Presence of other serious comorbidities resulting in an estimated survival of \\\u003C3 months.\n* Pregnant or breastfeeding women.","ALL","18 Years","100 Years",{"count":19,"type":20},10,"ESTIMATED","OBSERVATIONAL","A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures. Focusing on HER2-positive and TROP2-positive non-small cell lung cancer (NSCLC) cases, ADC candidates were screened for in vitro activity based on organoid-immune interaction models.\n\nKey assessments included:\n\nTumor killing efficiency, assessed by dose-response relationships; Drug internalization (cellular uptake), as a measure of penetration into cancer cells; Antibody-dependent cellular cytotoxicity (ADCC) and bystander effect, with negative control targets employed to delineate specificity; Single-cell RNA sequencing, to profile transcriptional alterations at single-cell resolution.\n\nData demonstrated distinct ADC responses correlating with target expression and immune microenvironment features. The integrated approach provided cell-based evidence of ADC potency and revealed mechanistic insights-including immune-mediated cytotoxicity pathways and intracellular trafficking-supporting the rational design of clinical trials. These findings established a foundation for precision immunotherapy strategies and offered a mechanistic rationale for patient selection in HER2\u002FTROP2-positive lung cancer.",[24],"HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer",[26,27,28],"Non-Small Cell Lung Cancer","HER2 Positive Non-Small Cell Lung Cancer","TROP2 Positive Non-Small Cell Lung Cancer","RECRUITING","2026-05-25",{"date":32,"type":33},"2026-05-28","ACTUAL",{"date":35,"type":33},"2025-12-28",{"date":37,"type":20},"2027-10-01",{"name":39,"class":40},"Guangzhou Institute of Respiratory Disease","OTHER"]